AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26763727 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 600 mg LD followed after 2 h by ticagrelor 180 mg re-LD
Number of subjects: 74
Study 25262934 — intervention group
Group type: EXPERIMENTAL
Intervention: High-oleic canola oil (HOCO)
Number of subjects: 36
Study 25262934 — intervention group
Group type: EXPERIMENTAL
Intervention: HOCO blended with flaxseed oil (FXCO)
Number of subjects: 36
Study 25262934 — intervention group
Group type: COMPARATOR
Intervention: Western diet (WD)
Number of subjects: 36
Study 22924356 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine 4% with 1:100 000 adrenaline delivered via Buccal Infiltration (BI)
Number of subjects: 57
Study 22924356 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine 2% with 1:80 000 adrenaline delivered via Buccal Infiltration (BI)
Number of subjects: 57
Study 22924356 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine 4% with 1:100 000 adrenaline delivered via Inferior Alveolar Nerve Block (IANB)
Number of subjects: 57
Study 22924356 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine 2% with 1:80 000 adrenaline delivered via Inferior Alveolar Nerve Block (IANB)
Number of subjects: 57
Study 19622592 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid eyedrops (CS), administered six times daily during docetaxel administration
Number of subjects: 20
Study 19622592 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (AT), administered six times daily during docetaxel administration
Number of subjects: 20
Study 18068062 — intervention group
Group type: COMPARATOR
Intervention: Air group (n = 26) - distal cuff inflated with 2 mL of air
Number of subjects: 52
Study 18068062 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline group (n = 26) - distal cuff inflated with 1.2 mL of saline
Number of subjects: 52
Study 15100507 — intervention group
Group type: EXPERIMENTAL
Intervention: Tl single photon emission computed tomography (SPECT) (38 patients)
Number of subjects: 80
Study 15100507 — intervention group
Group type: EXPERIMENTAL
Intervention: gated 99mTc-MIBI SPECT (42 patients)
Number of subjects: 80
Study 15100507 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiquantitative evaluation using SSS and SDS
Number of subjects: 80
Study 15100507 — intervention group
Group type: EXPERIMENTAL
Intervention: gated MIBI study
Number of subjects: 80
Study 11666119 — intervention group
Group type: EXPERIMENTAL
Intervention: Total triterpenic fraction of Centella asiatica (TTFCA) 60 mg twice daily for 12 months
Number of subjects: 0
Study 11666119 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similar tablets)
Number of subjects: 0
Study 9643140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive massage
Number of subjects: 30
Study 8134075 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 mg)
Number of subjects: 565
Study 8134075 — intervention group
Group type: COMPARATOR
Intervention: Control (no aspirin treatment)
Number of subjects: 565
Study 2570547 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrosine (alpha‐methylparatyrosine)
Number of subjects: 3
Study 2570547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 1085738 — intervention group
Group type: EXPERIMENTAL
Intervention: Flufenamic acid ointment (Mobilisin)
Number of subjects: 100
Study 1085738 — intervention group
Group type: COMPARATOR
Intervention: Control preparation
Number of subjects: 100
Study 31243069 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular nVNS of the left cervical vagal nerve
Number of subjects: 28
Study 31243069 — intervention group
Group type: COMPARATOR
Intervention: Sham I (stimulation of the posterior neck with the same device)
Number of subjects: 28
Study 31243069 — intervention group
Group type: COMPARATOR
Intervention: Sham II (stimulation of the left cervical vagal nerve with a sham device)
Number of subjects: 28
Study 28831953 — intervention group
Group type: EXPERIMENTAL
Intervention: TAKE 5 (multi-component weight management programme with energy deficit diet)
Number of subjects: 50
Study 28831953 — intervention group
Group type: COMPARATOR
Intervention: Waist Winners Too (health education programme)
Number of subjects: 50
Study 25297466 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI), structured 8-week program of mindfulness training
Number of subjects: 62
Study 25297466 — intervention group
Group type: COMPARATOR
Intervention: Psycho-oncological telephone consultation (control)
Number of subjects: 62
Study 25297466 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 62
Study 23498210 — intervention group
Group type: EXPERIMENTAL
Intervention: β-TCP
Number of subjects: 95
Study 23498210 — intervention group
Group type: COMPARATOR
Intervention: Allograft
Number of subjects: 95
Study 21878747 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical therapy
Number of subjects: 20
Study 21878747 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 20
Study 19332192 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (specifics not provided)
Number of subjects: 15603
Study 16505417 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg daily for 5 years)
Number of subjects: 1246
Study 16505417 — intervention group
Group type: COMPARATOR
Intervention: No tamoxifen
Number of subjects: 1246
Study 16505417 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1246
Study 16505417 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy-induced amenorrhea
Number of subjects: 1246
Study 15529636 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid 600mg daily IV for 10 days, then 600mg daily for 50 days
Number of subjects: 46
Study 15529636 — intervention group
Group type: COMPARATOR
Intervention: Control group (29 patients)
Number of subjects: 46
Study 16940816 — intervention group
Group type: EXPERIMENTAL
Intervention: CenteringPregnancy model of prenatal care, over 20 hours of contact time throughout pregnancy and early postpartum
Number of subjects: 0
Study 10551494 — intervention group
Group type: EXPERIMENTAL
Intervention: E2F-decoy treatment
Number of subjects: 41
Study 10551494 — intervention group
Group type: COMPARATOR
Intervention: Scrambled-oligodeoxynucleotide treatment
Number of subjects: 41
Study 10551494 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 41
Study 8728041 — intervention group
Group type: EXPERIMENTAL
Intervention: Home total parenteral nutrition (TPN; n = 16)
Number of subjects: 31
Study 8728041 — intervention group
Group type: COMPARATOR
Intervention: Dietary counselling (n = 15)
Number of subjects: 31
Study 1653362 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 at weekly doses of 100 mg/m2
Number of subjects: 17
Study 1653362 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 at weekly doses ranging from 50 to 150 mg/m2
Number of subjects: 17
Study 1653362 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 at weekly doses
Number of subjects: 17
Study 1653362 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11
Number of subjects: 17
Study 6218370 — intervention group
Group type: EXPERIMENTAL
Intervention: CI2MDP 1600 mg/d
Number of subjects: 13
Study 6218370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30846304 — intervention group
Group type: EXPERIMENTAL
Intervention: l-isoproterenol (10 μg/kg/h)
Number of subjects: 83
Study 30846304 — intervention group
Group type: COMPARATOR
Intervention: salbutamol (500 μg/kg/h)
Number of subjects: 83
Study 30193722 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational weight gain restriction program during pregnancy
Number of subjects: 262
Study 30193722 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 262
Study 25421635 — intervention group
Group type: EXPERIMENTAL
Intervention: Movies as a teaching resource
Number of subjects: 0
Study 24878629 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercising group (DS‐E)
Number of subjects: 42
Study 24878629 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising group (DS‐NE)
Number of subjects: 42
Study 21773676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 83
Study 21773676 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition
Number of subjects: 83
Study 18990500 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interventions (BMIs)
Number of subjects: 0
Study 17908264 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination program
Number of subjects: 82
Study 17908264 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intervention program
Number of subjects: 82
Study 17908264 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping intervention program
Number of subjects: 82
Study 15724764 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in a chemoprevention trial
Number of subjects: 0
Study 15724764 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased health awareness
Number of subjects: 0
Study 15724764 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal enhancement
Number of subjects: 0
Study 15724764 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociability
Number of subjects: 0
Study 11236045 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml sucrose 24% w/v
Number of subjects: 51
Study 11236045 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA plus sucrose
Number of subjects: 51
Study 11236045 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 51
Study 9593779 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding plus exogenous insulin (200 pmol/h = 28 U/h) with extra glucose as needed (I+G)
Number of subjects: 6
Study 9593779 — intervention group
Group type: COMPARATOR
Intervention: Continuous high‐carbohydrate enteral feeding alone (C)
Number of subjects: 6
Study 8005129 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg daily simvastatin
Number of subjects: 621
Study 8005129 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg daily simvastatin
Number of subjects: 621
Study 8005129 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 621
Study 31811485 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - treating team received PAT summary describing low, medium, or high psychosocial risk
Number of subjects: 183
Study 31811485 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - no summary provided to treating team
Number of subjects: 183
Study 30012233 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 50
Study 30012233 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (treatment as usual)
Number of subjects: 50
Study 26287876 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery
Number of subjects: 200
Study 26287876 — intervention group
Group type: COMPARATOR
Intervention: Conventional phacoemulsification
Number of subjects: 200
Study 23492671 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS and oral prednisone
Number of subjects: 375
Study 23492671 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 375
Study 23492671 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 375
Study 23492671 — intervention group
Group type: COMPARATOR
Intervention: BMS
Number of subjects: 375
Study 23492671 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 375
Study 23492671 — intervention group
Group type: EXPERIMENTAL
Intervention: DES
Number of subjects: 375
Study 23492671 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and DES
Number of subjects: 375
Study 22151834 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation counselling [S]
Number of subjects: 1100
Study 22151834 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation + PA counselling [S + PA]
Number of subjects: 1100
Study 22151834 — intervention group
Group type: COMPARATOR
Intervention: Control group [C]
Number of subjects: 1100
Study 19221059 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0-T MR imaging
Number of subjects: 31
Study 16546598 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate lotion 0.05% applied once daily for 4 weeks
Number of subjects: 438
Study 16546598 — intervention group
Group type: COMPARATOR
Intervention: Placebo lotion applied once daily for 4 weeks
Number of subjects: 438
Study 12778391 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard or high-dose cisplatin with etoposide and bleomycin
Number of subjects: 13
Study 12778391 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed surgical resection with organ preservation
Number of subjects: 13
Study 12778391 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin dose comparison
Number of subjects: 13
Study 10644301 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 0
Study 9349340 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2, 10 MU/mL)
Number of subjects: 10
Study 9349340 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour necrosis factor alpha (TNF-alpha, 10 micrograms/mL)
Number of subjects: 10
Study 9349340 — intervention group
Group type: COMPARATOR
Intervention: 1% histamine
Number of subjects: 10
Study 9349340 — intervention group
Group type: COMPARATOR
Intervention: Solvent control
Number of subjects: 10
Study 8103526 — intervention group
Group type: EXPERIMENTAL
Intervention: S-timolol (1 mg, 3 mg)
Number of subjects: 11
Study 8103526 — intervention group
Group type: EXPERIMENTAL
Intervention: R-timolol (25 mg, 75 mg)
Number of subjects: 11
Study 8103526 — intervention group
Group type: EXPERIMENTAL
Intervention: S-timolol (0.5 mg, 1 mg)
Number of subjects: 11
Study 8103526 — intervention group
Group type: EXPERIMENTAL
Intervention: R-timolol (3 mg, 10 mg)
Number of subjects: 11
Study 3788226 — intervention group
Group type: EXPERIMENTAL
Intervention: FCE 20700, 500 micrograms
Number of subjects: 0
Study 3788226 — intervention group
Group type: EXPERIMENTAL
Intervention: FCE 20700, 1500 micrograms
Number of subjects: 0
Study 3788226 — intervention group
Group type: EXPERIMENTAL
Intervention: FCE 20700, 500 micrograms and 1500 micrograms
Number of subjects: 0
Study 3788226 — intervention group
Group type: EXPERIMENTAL
Intervention: FCE 20700, 250 micrograms t.i.d.
Number of subjects: 0
Study 3788226 — intervention group
Group type: EXPERIMENTAL
Intervention: FCE 20700, 750 micrograms t.i.d.
Number of subjects: 0
Study 29724663 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose venlafaxine (up to 300 mg/day) plus problem-solving therapy (PST) for 10 weeks
Number of subjects: 227
Study 29724663 — intervention group
Group type: COMPARATOR
Intervention: High-dose venlafaxine with supportive management for 10 weeks
Number of subjects: 227
Study 29724663 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (PST and supportive management)
Number of subjects: 227
Study 30641622 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuling Powder (WP) combined with ventriculoperitoneal shunt surgery
Number of subjects: 56
Study 30641622 — intervention group
Group type: COMPARATOR
Intervention: Placebo decoction combined with ventriculoperitoneal shunt surgery
Number of subjects: 56
Study 23792312 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvalent mechanical bacterial lysate (PMBL)
Number of subjects: 0
Study 23792312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23401480 — intervention group
Group type: EXPERIMENTAL
Intervention: High power condition
Number of subjects: 3
Study 23401480 — intervention group
Group type: COMPARATOR
Intervention: Low power condition
Number of subjects: 3
Study 23401480 — intervention group
Group type: COMPARATOR
Intervention: Control power condition
Number of subjects: 3
Study 19942604 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler E/E' ratio
Number of subjects: 980
Study 19942604 — intervention group
Group type: COMPARATOR
Intervention: Conventional echocardiography
Number of subjects: 980
Study 19000603 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% nitrous oxide inhalation
Number of subjects: 26
Study 19000603 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nitrous oxide)
Number of subjects: 26
Study 19000603 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional music during sedation
Number of subjects: 26
Study 15728057 — intervention group
Group type: EXPERIMENTAL
Intervention: Frakefamide (FF) 1.22 mg/kg
Number of subjects: 12
Study 15728057 — intervention group
Group type: COMPARATOR
Intervention: Morphine (M-large) 0.43 mg/kg
Number of subjects: 12
Study 15728057 — intervention group
Group type: COMPARATOR
Intervention: Morphine (M-small) 0.11 mg/kg
Number of subjects: 12
Study 12856052 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (500 mg)
Number of subjects: 914
Study 12856052 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (40 or 80 mg)
Number of subjects: 914
Study 12856052 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with mebendazole and levamisole
Number of subjects: 914
Study 12856052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 914
Study 10565560 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk formula (CMF)
Number of subjects: 129
Study 10565560 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk (HM)
Number of subjects: 129
Study 10565560 — intervention group
Group type: COMPARATOR
Intervention: Casein hydrolysate formula (CHF)
Number of subjects: 129
Study 10565560 — intervention group
Group type: EXPERIMENTAL
Intervention: All feeding groups (CMF, HM, CHF)
Number of subjects: 129
Study 8604417 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 0
Study 8604417 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 0
Study 8604417 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (Atrovent)
Number of subjects: 0
Study 8604417 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal and influenza vaccinations
Number of subjects: 0
Study 1715152 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-sleeping (102 babies)
Number of subjects: 203
Study 1715152 — intervention group
Group type: COMPARATOR
Intervention: Crib care (101 babies)
Number of subjects: 203
Study 7153946 — intervention group
Group type: EXPERIMENTAL
Intervention: VT (10 sessions)
Number of subjects: 16
Study 7153946 — intervention group
Group type: EXPERIMENTAL
Intervention: VT (5 sessions) and CT (5 sessions)
Number of subjects: 16
Study 7153946 — intervention group
Group type: EXPERIMENTAL
Intervention: CT (10 sessions)
Number of subjects: 16
Study 7153946 — intervention group
Group type: EXPERIMENTAL
Intervention: CT (5 sessions) and VT (5 sessions)
Number of subjects: 16
Study 7153946 — intervention group
Group type: COMPARATOR
Intervention: Waiting control
Number of subjects: 16
Study 7153946 — intervention group
Group type: EXPERIMENTAL
Intervention: EG-1a (VT)
Number of subjects: 16
Study 7153946 — intervention group
Group type: EXPERIMENTAL
Intervention: EG-11a (CT)
Number of subjects: 16
Study 7153946 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training groups
Number of subjects: 16
Study 7153946 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 16
Study 31030379 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (660 nm, 100 mW, 2 J, 66.66 J/cm2, 3.3 W/cm2, 20 s of irradiation, punctual, and continuous mode)
Number of subjects: 80
Study 31030379 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser treatment)
Number of subjects: 80
Study 26998803 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 193
Study 26998803 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 193
Study 26998803 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WLC)
Number of subjects: 193
Study 27220593 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery pressure-guided management (treatment group)
Number of subjects: 245
Study 27220593 — intervention group
Group type: COMPARATOR
Intervention: Control group (symptoms and daily weights alone)
Number of subjects: 245
Study 25591638 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin
Number of subjects: 1450
Study 25591638 — intervention group
Group type: COMPARATOR
Intervention: Control (no cytoflavin)
Number of subjects: 1450
Study 24761313 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental diet containing eicosapentaenoic acid (EPA), gamma‐linolenic acid (GLA), docosahexaenoic acid, and antioxidants (n=9)
Number of subjects: 17
Study 24761313 — intervention group
Group type: COMPARATOR
Intervention: Isonitrogenous, isocaloric standard diet (n=8)
Number of subjects: 17
Study 19811949 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 min rest interval (G3)
Number of subjects: 36
Study 19811949 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 min rest interval (G5)
Number of subjects: 36
Study 19811949 — intervention group
Group type: COMPARATOR
Intervention: 1 min rest interval (G1)
Number of subjects: 36
Study 17968976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 40
Study 17968976 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 40
Study 17968976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16192511 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL anesthetic solution
Number of subjects: 0
Study 16192511 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL anesthetic solution
Number of subjects: 0
Study 16192511 — intervention group
Group type: COMPARATOR
Intervention: Both groups (3 mL and 5 mL)
Number of subjects: 0
Study 14599236 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal recall
Number of subjects: 0
Study 14599236 — intervention group
Group type: EXPERIMENTAL
Intervention: MTLC familiarity signal
Number of subjects: 0
Study 14599236 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulations of target-lure similarity and interference
Number of subjects: 0
Study 14599236 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial versus complete hippocampal lesions
Number of subjects: 0
Study 10962319 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (exact intervention not specified)
Number of subjects: 247